Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2010

Cardiac signaling genes exhibit unexpected sequence diversity in
sporadic cardiomyopathy, revealing HSPB7 polymorphisms
associated with disease
Scot J. Matkovich
Washington University School of Medicine in St. Louis

Derek J. Van Booven
Washington University School of Medicine in St. Louis

Anna Hindes
Washington University School of Medicine in St. Louis

Min Young Kang
Washington University School of Medicine in St. Louis

Todd E. Druley
Washington University School of Medicine in St. Louis

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Matkovich, Scot J.; Van Booven, Derek J.; Hindes, Anna; Kang, Min Young; Druley, Todd E.; Vallania,
Francesco L.M.; Mitra, Robi D.; Reilly, Muredach P.; Cappola, Thomas P.; and Dorn, Gerald W. II, ,"Cardiac
signaling genes exhibit unexpected sequence diversity in sporadic cardiomyopathy, revealing HSPB7
polymorphisms associated with disease." The Journal of Clinical Investigation. 120,1. 280-289. (2010).
https://digitalcommons.wustl.edu/open_access_pubs/1625

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Scot J. Matkovich, Derek J. Van Booven, Anna Hindes, Min Young Kang, Todd E. Druley, Francesco L.M.
Vallania, Robi D. Mitra, Muredach P. Reilly, Thomas P. Cappola, and Gerald W. Dorn II

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/1625

Downloaded on August 23, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/39085

Research article

Cardiac signaling genes exhibit
unexpected sequence diversity in sporadic
cardiomyopathy, revealing HSPB7
polymorphisms associated with disease
Scot J. Matkovich,1 Derek J. Van Booven,1 Anna Hindes,1 Min Young Kang,1
Todd E. Druley,2,3 Francesco L.M. Vallania,3 Robi D. Mitra,3 Muredach P. Reilly,4
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for Genome Sciences, Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.
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Sporadic heart failure is thought to have a genetic component, but the contributing genetic events are poorly
defined. Here, we used ultra-high-throughput resequencing of pooled DNAs to identify SNPs in 4 biologically
relevant cardiac signaling genes, and then examined the association between allelic variants and incidence of
sporadic heart failure in 2 large Caucasian populations. Resequencing of DNA pools, each containing DNA
from approximately 100 individuals, was rapid, accurate, and highly sensitive for identifying common and
rare SNPs; it also had striking advantages in time and cost efficiencies over individual resequencing using
conventional Sanger methods. In 2,606 individuals examined, we identified a total of 129 separate SNPs in
the 4 cardiac signaling genes, including 23 nonsynonymous SNPs that we believe to be novel. Comparison of
allele frequencies between 625 Caucasian nonaffected controls and 1,117 Caucasian individuals with systolic
heart failure revealed 12 SNPs in the cardiovascular heat shock protein gene HSPB7 with greater proportional
representation in the systolic heart failure group; all 12 SNPs were confirmed in an independent replication
study. These SNPs were found to be in tight linkage disequilibrium, likely reflecting a single genetic event, but
none altered amino acid sequence. These results establish the power and applicability of pooled resequencing
for comparative SNP association analysis of target subgenomes in large populations and identify an association between multiple HSPB7 polymorphisms and heart failure.
Introduction
Application of genetic testing and linkage analysis to rare inherited
disorders has uncovered thousands of causative genetic mutations
and revealed much about disease pathophysiology and process (1).
Identifying genetic causes for common diseases such as hypertension, diabetes, and heart failure has proven more challenging, likely
because these complex syndromes develop as a consequence of
interactions among multiple genetic and nongenetic factors. Furthermore, familial transmission of these disorders is inconsistent,
disease penetrance tends to be incomplete, and the phenotypes can
be highly variable. For these reasons, attempts to delineate genetic
influences in common diseases have eschewed studies of familial
transmission in favor of large-scale genetic association analyses that
compare the frequencies of gene variants between affected cases
and nonaffected controls. Genetic mapping of SNPs located at set
intervals across the entire genome of thousands of individuals using
microarray-based platforms has reproducibly implicated specific
genetic loci in cancer, diabetes, hypertension, coronary atherosclerosis, and other diseases (2–6). However, assignment of the basis for
gene effects and advancing our understanding into disease mechanisms requires resequencing across linked loci to identify causal
mutations. In many cases, this has not yet been achieved.
Conflict of interest: The authors have declared that no conflict of interest exists.
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Polygenic models for complex diseases propose that a significant
component of genetic susceptibility is found in combinatorial
interactions of multiple rare deleterious mutations (7, 8). Accordingly, the ultimate goal for studies correlating genotype and phenotype should be to identify all gene variants at multiple loci, both
common and rare. This requires deep resequencing in very large
and well-characterized patient populations (9). A first step is the
NIH 1,000 Genomes Project, in which entire individual genomes
are being independently resequenced at an estimated cost of at
least $30 million and will be collectively analyzed to generate a map
of all human allelic variants with a frequency greater than 1% (10).
More time- and cost-efficient gene mapping and identification of
genetic modifiers for common diseases could be accomplished
by targeted genetic analysis of pooled case and control samples.
However, pooled genotyping is not compatible with conventional
Sanger or microarray-based sequencing techniques.
We recently developed a targeted, pooled sample sequencing
strategy (11) that, coupled with novel computational algorithms
and second-generation DNA sequencing platforms (12, 13), accurately identified the position and frequency of common and rare
SNPs in a random pediatric population of 1,111 individuals. Here,
we have explored the applicability of these techniques to catalog
nucleotide sequence diversity in a large adult population and to
perform a SNP association study of systolic heart failure in 4 biologically relevant cardiac signaling genes: α1-adrenergic receptor
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Figure 1
Position of 129 signaling gene SNPs identified by
pooled sequencing. Schematics show the exonic
structure of the 4 target genes. Black boxes represents coding regions; white boxes represent 5′
and 3′ untranslated regions. Genomic PCR primer
positions are shown with arrows. Detected SNPs
are indicated by position and numbering from
translation start site. Black lines indicate SNPs
in dbSNP (19); red lines indicate novel SNPs. (A)
Results for Caucasians (Cauc). (B) Results for
African Americans (AA).

haplotype block of 12 synonymous or intronic
HSPB7 SNPs in tight linkage disequilibrium
that were significantly and reproducibly associated with systolic heart failure.

(ADRA1A), β2-adrenergic receptor (ADRB2; refs. 14, 15), phospholamban (PLN; refs. 16, 17), and the cardiovascular heat shock
protein (HSP) gene HSP27 member 7 (HSPB7; ref. 18). SNP calling using pooled sample resequencing was reproducible and, in
comparison with individual Sanger sequencing of ADRA1A exon 2,
both accurate and sensitive. We identified 55 common SNPs (common defined in the present study as greater than 1% overall allele
frequency within a population of similar geographic ancestry) and
74 rare SNPs (rare defined as less than 1% overall allele frequency).
Of these, 7 common SNPs were nonsynonymous (i.e., the genetic
alteration changed an encoded amino acid), all of which are previously described in the SNP database (dbSNP; ref. 19), and 29 rare
SNPs were nonsynonymous, 23 of which were novel. Comparison
of common SNP allele frequencies in a Caucasian population
(where Caucasian is defined as mixed European descent) between
systolic heart failure cases and nonaffected controls revealed a

Results
Pooled DNA resequencing to detect and quantify SNPs
in a large population. To catalog nucleotide variations within the 4 target gene exons, we amplified and resequenced 5 loci covering 9.4 kb of
nonamplified genomic DNA archived from 2,606
individuals — 1,742 Caucasians and 864 African
Americans — who had participated in a longitudinal study of systolic heart failure (20). The
coding regions for ADRA1A, ARDB2, HSPB7, and
PLN were comprehensively examined (Figure 1).
In initial studies determining the capabilities
and limits of our pooled resequencing approach,
genomic DNA from the study population was
combined into 12 DNA pools of approximately
250 individuals per pool.
To determine the consistency of SNP calling
by Illumina Genome Analyzer resequencing and
our analysis pipeline, sequencing libraries were
prepared from the 12 DNA pools and separately
amplified and sequenced on 2 different machines
at 2 different times. The data were analyzed in
an identical manner, and allele frequencies were
compared. The reported allele frequencies for
confirmed SNPs were highly concordant between
the 2 sequencing runs across the entire range
(r2 = 0.991; P = 9 × 10–122; Figure 2A).
Next, we evaluated the reproducibility of SNP identification and
quantification as a function of preparing different sequencing
libraries from the same DNA pools, or of starting with different
DNA pools prepared from the same group of individual DNAs.
This comparison examined variability introduced by differences
in DNA handling and amplification. The correlation of reported
allele frequencies in different sequencing libraries prepared from
identical pools was as good as that from libraries prepared from
different pools containing the same collection of individual DNAs
(r2 = 0.993 and 0.994, respectively; P < 1 × 10–70; Figure 2, B and C).
Depth of sequence coverage using the pooled DNA sequencing approach is determined in part by the number of individual
genomes added per single Illumina lane; for our experimental
design, this corresponded with the number of individuals in
each pool. For our initial studies using 12 pools of about 250
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Figure 2
Allele frequency comparisons with Illumina resequencing of pooled DNA. (A) Comparison of SNP allele frequencies from 2 independent runs of identical sequencing libraries made from 12 pools of 2,606 individual
DNAs. (B) Comparison of SNP allele frequencies from
2 independent runs of separate libraries made from
the same DNA pools. (C) Comparison of SNP allele
frequencies from 2 independent runs of libraries made
from replicate DNA pools. (D) Comparison of SNP allele
frequencies obtained from resequencing the same
2,606 individual DNAs, grouped into pools of approximately 250 individual DNAs (12 pools) versus approximately 100 individual DNAs (29 pools). Formulae for
regression line and Pearson correlation coefficient are
indicated for each analysis.

individuals, sequence coverage for SNP calling (first 12 nucleotides only) averaged 10-fold per diploid genome. Coverage depth
for the noncoding region of PLN, which has low sequence complexity due to the presence of multiple dinucleotide repeats, was
not as great (3-fold per diploid genome). To assess the impact of
increasing sequence coverage on SNP calling, we resequenced the
5 genetic loci in the study cohort divided into 29 pools containing
approximately 100 individual DNAs (range, 75 to 125). With this
DNA pooling design and intercurrent improvements in Illumina
sequencing chemistry (21), and by sequencing the library from
each pool in a separate lane, we found average sequence coverage
depth increased to 43-fold (11-fold for PLN noncoding).
SNP identification was compared between the 250 individuals
per pool (12-pool) and 100 individuals per pool (29-pool) studies. A total of 129 separate SNPs (55 common, 74 rare) were identified and validated in the 29-pool study. Correlation of allele
frequencies for SNPs reported in both the 12- and 29-pool studies was excellent (r 2 = 0.990, P = 4.2 × 10–115; Figure 2D). Of 81
SNPs reported in the 12-pool study, 77 (95%) were detected in the
29-pool study, but 49 validated SNPs reported in the 29-pool
design had not fulfilled validation criteria in the 12-pool studies.
Of these newly validated SNPs, 47 were rare (Caucasians, median
allele frequency 0.0008, range 0.0003 to 0.005; African Americans,
median allele frequency 0.014, range 0.0006 to 0.019), and 2 were
private (Caucasians, allele frequency 0.0003; African Americans,
allele frequency 0.0006). Thus, DNA pooling into smaller groups of
about 100 individuals improved detection of rare SNPs by increasing sequence coverage depth and by affording greater opportunity
for SNP calling in multiple different pools.
We examined the sensitivity and specificity of Illumina pooled
resequencing in comparison to the previous gold standard, conventional Sanger resequencing of individual DNAs. Pooled sequencing
showed that the 5′ end of the ADRA1A exon 2 contains 15 SNPs
(7 reported in HapMap and 8 novel), with allele frequencies ranging from approximately 50% to a singleton (Figure 1 and Table 1).
282

Therefore, we individually Sanger resequenced this amplicon for
each subject DNA. Of the 2,606 DNAs amplified and submitted,
confident Sanger sequence was returned on 2,506 (1,666 Caucasians and 840 African Americans; 96% overall sequence success
rate). SNP allele frequencies generated by pooled and individual
resequencing are compared in Table 1, reported separately for
Caucasians and African Americans. Pooled Illumina resequencing
and individual Sanger resequencing identified the same 15 SNPs.
Pooled sequencing detected 5 confirmed singletons in the Caucasian subgroup (+1,074, +1,172, +1,203, +1,311, and +1,443) and
1 SNP that occurred only twice in this group (+927). However,
within the Caucasian and African American subgroups, pooled
resequencing failed to detect a rare SNP in the Caucasian subgroup
that was detected on Sanger sequence (+996); this also occurred
once in the African American cohort (+1,124). In both instances, the
SNP had been bioinformatically filtered from the pooled sequencing results because it was novel and not detected in more than 1
DNA pool, or in both the 29-pool and 12-pool studies. For the
3 common SNPs (+1,039, +1,395, and +1,617), the allele frequencies
generated by pooled Illumina sequencing were comparable to those
from individual Sanger sequencing. These results show that allele
frequencies for common SNPs obtained by Illumina resequencing
of pools of about 100 individual DNAs were sufficiently accurate
for between-group comparisons. These data also demonstrate that
pooled resequencing and our analysis pipeline can be highly sensitive for the detection of rare and private SNPs in large populations,
although stochastic variation and our filtering criteria made for
less than absolute sensitivity in all pools. Based on this finding,
we determined that quantitative comparisons of individual SNP
allele frequencies between population groups are best performed
on common SNPs and that a more qualitative approach should be
used to evaluate rare and private SNPs.
Allele frequencies in population subgroups with different geographic ancestries. Resequencing target genes across a large population should be
useful to identify alleles that are differentially represented between

The Journal of Clinical Investigation    http://www.jci.org    Volume 120    Number 1    January 2010

Downloaded on August 23, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/39085

research article
Table 1
ADRA1A exon 2 SNP allele frequencies from pooled Illumina versus individual Sanger sequencing

cially those that are not represented
on marker SNP arrays) that are
differentially represented between
diseased cases and nonaffected condbSNP
Position
Type
Major Minor Codon
Pooled Illumina
Individual Sanger
trols. Accordingly, we used pooled
allele allele
Cauc
AA
Cauc
AA
DNA resequencing for a case-con+927
Coding S
A
G
K309K
0.0004
–
0.0006
–
trol gene association study of systol+996
Coding S
G
A
E332E
–
0.0014
0.0009 0.0027
ic heart failure among Caucasians.
rs1048101 +1,039 Coding NS
T
C
C347R
0.4373 0.7435
0.4856 0.7611
rs56318220 +1,074 Coding S
C
T
Y358Y
0.0003
–
0.0004
–
We compared allele frequencies for
rs61731555 +1,123 Coding NS
G
T
V375L
–
0.0017
–
0.0016
the 37 common SNPs identified in
+1,124 Coding NS
T
G
V375G
0.0006
–
0.0015 0.0024
our pooled DNA resequencing of
+1,172 Coding NS
C
T
T391M
0.0003
–
0.0004
–
1,117 Caucasian heart failure cases
+1,173 Coding S
G
A
T391T
–
0.0023
–
0.0031
(the 29-pool study) with 625 Cau+1,203 Coding S
T
G
S401S
0.0004 0.0019
0.0004 0.0031
casian controls from the University
+1,311 Coding S
G
T
G437G
0.0003
–
0.0004
–
of Cincinnati, and confirmed assors2229126 +1,395 Coding NS
A
T
E465D
0.0308 0.0278
0.0232 0.0221
ciated SNPs in a replication pooled
C
A		
0.0003 0.0008
0.0004
–
+1,443
3′UTR
sequencing analysis of 859 Caucars61760513 +1,460
3′UTR
C
A		
0.0003 0.0062
0.0009 0.0043
sian heart failure cases and 311 Caurs61760511 +1,563
3′UTR
G
T		
0.0035 0.0013
0.0048 0.0035
rs73678233 +1,617
3′UTR
C
T		
0.0012 0.0661
0.0015 0.0487
casian controls from the University
of Pennsylvania. Detailed clinical
Illumina sequencing was performed on 19 pools of 1,742 Caucasians (Cauc) and 9 pools of 864 African
characteristics of the systolic heart
Americans (AA). Sanger sequencing was successful for 1,666 Caucasians and 840 African Americans
failure study population, stratified
assayed individually. For SNPs in HapMap, the rs number from dbSNP (19) is shown. Position is from the
translation initiation codon. S, synonymous; NS, nonsynonymous; UTR, untranslated region. Values in the
by geographic ancestry, have been
codon column show the amino acid. Allele frequencies of ~0.0003 and ~0.0006 correspond to singletons in
reported elsewhere (20). A summary
Caucasians and African Americans, respectively.
of demographic and clinical features
of the study subjects is shown in
Table 3. The DNA pooling strategy
population subgroups. We recently showed that differences in for the study groups is shown in Supplemental Figure 1.
SNP frequency between 2 groups with different genetic ancestries
Our 4 target genes were selected because of their postulated relcan confound the results of systolic heart failure outcome stud- evance to cardiac physiology and disease (22–24). Therefore, we were
ies when genotype is not an a priori consideration in experimental gratified to find genotype-phenotype associations (Table 4 and Supdesign (20). Racial differences in SNP frequencies are reported in plemental Table 2). Of the 37 common SNPs analyzed in the casethe HapMap, but the number of individuals from some ancestral control cohort, 12 SNPs spanning exons 1–3 of HSPB7, including in
subgroups can be small. Therefore, we used pooled DNA resequenc- the intervening 2 introns, achieved the P < 0.0014 (α = 0.05) threshing to examine SNP diversity within our 4 target genes in 625 Cau- old for significance in the primary cohort (Figure 3B and Table 4).
casian and 236 African American subjects who did not have heart These SNPs were in tight linkage disequilibrium (Figure 3B), and
disease at the time of study entry. A total of 110 SNPs were detected therefore likely indicate a common genetic event. The association of
in the normal subjects, 48 of which were novel (Table 2 and Supple- each of these HSPB7 SNPs was replicated in a subsequent study of
mental Table 1; supplemental material available online with this independent heart failure cases and controls (P < 0.0211; α = 0.05;
article; doi:10.1172/JCI39085DS1). We found 27 SNPs to be non- effective number of independent SNPs, 2.36; Table 4).
synonymous (encoded a change in amino acid), 16 of which were
The heart failure study cohorts consisted of a mixture of ischnovel (Table 2 and Supplemental Table 1). Even though our sample emic and nonischemic (also known as idiopathic) cardiomyopanumber for African Americans was only about one-third that for thies, but our DNA pooling strategy permitted us to separately
Caucasians, African Americans had 84 SNPs compared with 69 in examine the association of HSPB7 polymorphisms with each etiCaucasians. Moreover, 41 SNPs were exclusive to African Americans ology. In the primary cohort of 691 with ischemic cardiomyopa(including 7 in the 3′ untranslated region of ADRB2 and 15 in the thy and 426 with nonischemic cardiomyopathy, multiple SNPs
second intron and third exon of HSPB7), and 26 SNPs were exclu- within the HSPB7 haplotype block were significant in both etiosive to Caucasians (including 12 in the coding region of ADRA1A logical subgroups (Supplemental Table 3), which suggests that the
and 7 in the coding region of ADRB2; Supplemental Table 1 and association of this HSPB7 haplotype applies to both ischemic and
Figure 3A). Of the 42 SNPs present in both population subgroups, nonischemic cardiomyopathies.
the allele frequencies differed significantly (P < 0.0005; α = 0.05)
Although we were underpowered to perform a comprehensive
between African Americans and Caucasians in 27, and in 24 of these SNP association analysis of African American systolic heart failure,
instances, the allele frequency was significantly greater in African we examined our limited cohort of 628 African American cases and
Americans (Table 2 and Figure 3A). These results reveal substantial 236 African American controls to determine whether any of the
nucleotide sequence diversity in the 4 target genes as a function HSPB7 SNP associations detected in the primary Caucasian cohort
of geographic ancestry and support SNP association study designs were present in this subgroup. African American systolic heart failthat analyze Caucasians and African Americans separately.
ure was similar to Caucasian heart failure in terms of age, height,
Common signaling gene polymorphisms associated with systolic heart fail- weight, and degree of left ventricular dysfunction (ejection fracure. Another instance in which pooled resequencing should have tion), but, consistent with previous observations (25, 26), hypertenadvantages over individual resequencing is to identify alleles (espe- sion and nonischemic cardiomyopathy were more prevalent (20).
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Table 2
Comparative allele frequencies of target gene SNPs in Caucasians and African Americans
dbSNP
ADRA1A
rs2229125
rs382423
rs14811
rs2229126
rs6176513
rs6176511
rs73678233
rs3739216
ADRB2
rs142711
rs18174
rs142713
rs142714
rs142717
rs142718
rs142719
rs14272
rs8192451
HSPB7
rs373864
rs945416
rs732286
rs3883891
rs1739845
rs3738643
rs1739844
rs1763597
rs1739843
rs12758813
rs1739842
rs1763598
rs1739841
rs1763599
rs61783988
rs76176
rs761759
rs173984
PLN
rs73526175
rs12198461
rs9489441
rs151429

Position

Type

+320
+599
I1+53
+1,039
+1,395
+1,460
+1,563
+1,617
+1,818

Coding NS
Coding NS
Intronic
Coding NS
Coding NS
3′UTR
3′UTR
3′UTR
3′UTR

–47
–20
+46
+79
+252
+523
+1,053
+1,239
+1,620

Major Minor
allele allele

Codon

Cauc
controls

AA
controls

P

T
T
G
T
A
C
G
C
C

G
V17G
G
I200S
T		
C
C347R
T
E465D
A		
T		
T		
G		

0.0024
0.0216
0.0162
0.4317
0.0243
0.0008
0.0030
0.0011
0.0742

0.0079
0.0017
0.0095
0.7023
0.0226
0.0110
0.0021
0.0591
0.1800

0.0945
0.0022
0.3555
<0.0001A
1.0000
0.0071
1.0000
<0.0001A
<0.0001A

5′UTR
5′UTR
Coding NS
Coding NS
Coding S
Coding S
Coding S
Coding S
3′UTR

C
C
G
G
G
C
G
G
C

T		
T		
A
G16R
C
E27Q
A
L84L
A
R175R
C
G351G
A
L413L
T		

0.6161
0.6185
0.3985
0.5716
0.2165
0.2004
0.2995
0.3256
0.0150

0.8451
0.8415
0.4781
0.8165
0.3965
0.3892
0.3851
0.5402
0.0064

<0.0001A
<0.0001A
0.0031
<0.0001A
<0.0001A
<0.0001A
0.0008A
<0.0001A
0.2267

–8
+57
+99
I1+177
I1–113
I2+245
I2+247
I2+272
I2+315
I2+490
I2–594
I2–483
I2–473
I2–348
I2–343
I2–165
I2–96
+351

5′UTR
Coding S
Coding S
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Coding S

G
C
T
A
G
C
A
G
A
C
A
A
T
G
T
T
T
C

A		
T
S19S
C
A33A
G		
T		
G		
G		
A		
G		
T		
C		
G		
C		
A		
C		
C		
A		
T
T117T

0.1061
0.5383
0.5171
0.3730
0.0501
0.1116
0.5109
0.5276
0.5432
0.4173
0.5235
0.8775
0.4802
0.6009
0.0779
0.5307
0.5519
0.4735

0.0410
0.6737
0.6639
0.3590
0.0788
0.0404
0.6735
0.6988
0.7014
0.4350
0.6975
0.8424
0.6451
0.7442
0.0305
0.6803
0.7080
0.3096

<0.0001A
<0.0001A
<0.0001A
0.5762
0.0369
<0.0001A
<0.0001A
<0.0001A
<0.0001A
0.5476
<0.0001A
0.0662
<0.0001A
<0.0001A
0.0002A
<0.0001A
<0.0001A
<0.0001A

I1–206
I1–105
+556
+1,575
+1,736
+1,737

Intronic
Intronic
3′UTR
3′FR
3′FR
3′FR

G
A
T
G
G
C

T		
G		
G		
A		
C		
T		

0.0030
0.0013
0.5238
0.0209
0.0029
0.7017

0.0710
0.0043
0.4181
0.0624
0.0781
0.7003

<0.0001A
0.3029
<0.0001A
<0.0001A
<0.0001A
0.9529

Allele frequencies from Illumina resequencing of 7 DNA pools from 625 nonaffected Caucasians and 3
DNA pools from 237 nonaffected African Americans. For SNPs in HapMap, the rs number from dbSNP
(19) is shown. Position of exonic SNPs is relative to +1 position of the translation initiation codon, and of
SNPs within introns is relative to the nearest exon. I1, first intron; I2, second intron; S, synonymous; NS,
nonsynonymous; UTR, untranslated region; FR, flanking region. Values in the codon column show the
amino acid. Only those SNPs found to occur in both Caucasian and African Americans are shown; Supplemental Table 1 shows all 110 SNPs. AP < 0.0005, the threshold for this study (α = 0.05, n = 110).

There was no association among any of the HSPB7 SNPs with systolic heart failure in African Americans (Supplemental Table 4).
Impact of nonsynonymous signaling gene polymorphisms on systolic
heart failure. Our case-control study of systolic heart failure in
284

Caucasians examined only common
SNPs. Although 3 of the 12 associated HSPB7 SNPs were in coding
exons, they did not alter amino acid
sequence (Figure 3B and Table 4).
Nevertheless, it is estimated that 50%
of rare nonsynonymous SNPs can
be deleterious (27). For this reason,
we investigated the impact on heart
failure by rare and common nonsynonymous SNPs in the 4 target
genes. First, we used computational
algorithms SIFT and PolyPhen (28,
29) to categorize the likelihood that
the nonsynonymous SNPs could be
harmful, based upon sequence conservation, protein structure, and
annotated protein features. All coding SNPs in the target genes were
classified as either synonymous
(expected to be biologically neutral),
nonsynonymous and presumed
benign (both algorithms agreed),
nonsynonymous and presumed
pathological (both algorithms
agreed), or nonsynonymous with
uncertain consequences (algorithms
differed) (Supplemental Tables 5
and 6). Case-control comparisons
of allele frequencies were performed
for common SNPs (analyzed individually; Supplemental Table 5) and
rare SNPs (analyzed individually
and collectively as functionally similar groups; Supplemental Table 6).
For common SNPs, there were 7
nonsynonymous SNPs, only one of
which (ADRA1A I200S) was classified as presumed pathological.
Allele frequencies for this SNP were
approximately 0.02 in Caucasians
and approximately 0.002 in African Americans, with no differences
between heart failure cases and controls. For rare SNPs, there were 29
nonsynonymous SNPs (of which 16
were in ADRA1A): 13 were classified
as presumed benign, 10 as presumed
pathological, and 6 as uncertain
(Supplemental Table 6). Again, there
were no differences in allele frequencies between heart failure cases and
controls for these SNPs, either individually or combined into functionally similar groups.

Discussion
Here, we used large-scale pooled sequencing of phenotypically
similar individuals to identify and quantify common and rare
SNPs in a target cardiac signaling subgenome and applied this

The Journal of Clinical Investigation    http://www.jci.org    Volume 120    Number 1    January 2010

Downloaded on August 23, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/39085

research article
Figure 3
Comparative analysis of SNP allele frequencies in
population subgroups. (A) Comparison of target gene
SNP allele frequencies in African Americans versus
Caucasians. Vertical axis is African American allele
frequency/Caucasian allele frequency, plotted on a
log10 scale. Horizontal axis shows target gene with
SNPs positioned accordingly, as in Figure 1. Red symbols denote novel SNPs. The shaded area indicates
less than 2-fold difference in relative allele frequency.
Symbols at the extreme top and bottom represent
alleles seen exclusively in African Americans and
Caucasians, respectively (see Table 2). (B) Linkage
analysis of HSPB7 SNPs in Caucasians and association with systolic heart failure. HSPB7 SNP positions
are shown within the gene (schematic as in Figure 1;
boxes denote SNPs present in HapMap). Allele frequencies were compared across pools of 100 individuals. Red shading in the linkage plot denotes r 2 ≥ 0.90;
blue shading denotes r 2 > 0.70; no shading denotes
r 2 < 0.70. Numbers within plot show r 2 values (×100).
Asterisks denote SNPs significantly associated with
Caucasian heart failure (P < 0.0014; see Table 4).

information to a case-control SNP association analysis of sporadic ischemic and nonischemic cardiomyopathy. To our knowledge,
this is the first large-scale application of next-generation sequencing technologies to study a disease using pooled DNA samples;
therefore, we were careful to validate the approach and to replicate our findings, both within the primary study cohort and in an
independent systolic heart failure cohort. We found that Illumina resequencing of DNA pools containing about 100 individual
DNAs was rapid, accurate, and highly sensitive for identifying
common and rare or private SNPs and had striking advantages
in time and cost efficiencies over individual resequencing. Our
results identified, and verified by independent replication, a cluster of SNPs within a haplotype block of HSPB7 that were associated with development of systolic heart failure. Interestingly, none
of the associated SNPs altered amino acid coding of HSPB7 protein, nor were nonsynonymous SNPs independently associated
with heart failure, even those predicted to be functionally deleterious. The present studies demonstrate the power and potential
broad applicability of pooled resequencing for comparative SNP
association analysis of target subgenomes in large populations
and describe what we believe to be a previously unsuspected association between HSPB7 and sporadic heart failure.

Applicability of pooled resequencing with next-generation platforms.
Much of the low-hanging fruit from human genetic studies has
been picked over. Thousands of disease-causing gene mutations
have been identified, and millions of relatively common gene
polymorphisms have been cataloged, yet the impact of these findings has primarily been on rare inherited diseases that are almost
entirely genetic in cause. The next step is to elucidate the more
modest genetic effects attributable to simultaneous influences of
multiple noncausal gene variants on common diseases that are not
primarily genetic (8). This requires sequencing many thousands of
individual human genomes at a resolution of individual nucleotides, which we accomplished via a recently developed and validated pooled sequencing strategy (11). Our procedure accurately
detected variant alleles across a wide range of frequencies in Caucasian and African American normal controls and in heart failure
subjects. Results for ADRA1A exon 2, in which there were SNPs
covering the entire range of allele frequencies (but no difference in
allele frequencies between heart failure cases and controls), were
confirmed by individual Sanger sequencing of the entire study
cohort. Importantly, this pooled sequencing protocol generated
these data for a much smaller investment of time and resources
compared with conventional methods that rely upon serial geno-
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Table 3
Clinical characteristics of study cohorts
Primary controls
Variable
N
Age (yr)
Height (in.)
Weight (lb)
Ejection fraction (%)
CHF etiology (n)
Ischemic
Nonischemic
Female
Hypertension

Primary CHF

Secondary controls

Secondary CHF

Cauc

AA

Cauc

AA

Cauc

Cauc

625
48.74 ± 12.0
67.6 ± 4.2
182.7 ± 45.1
–

236
54.0 ± 13.3
66.4 ± 5.01
194.3 ± 46.5
–

1,117
57.1 ± 13.2
67.7 ± 4.1
193.0 ± 50.0
28.7 ± 13.2

628
54.0 ± 13.3
67.0 ± 4.2
197.2 ± 55.9
26.9 ± 11.5

311
58.0 ± 10.9
67.7 ± 4.0
186.4 ± 43.7
66.0 ± 6.3

859
58.5 ± 13.1
68.2 ± 4.0
189.2 ± 44.5
31.8 ± 16.2

–
–
375 (60%)
16 (3%)

–
–
184 (77%)
1 (0%)

689 (60%)
427 (40%)
359 (32%)
794 (69%)

295 (47%)
332 (53%)
285 (46%)
568 (91%)

–
–
138 (44%)
144 (47%)

286 (50%)
285 (50%)
158 (28%)
252 (44%)

typing of each individual in each cohort. Extrapolating the time
and cost of individual capillary resequencing versus Illumina resequencing of pools of about 100 individual DNAs (referred to herein as the 29-pool study), accurate allele frequencies and detection
of very rare and private SNPs was achieved in the current instance
for one-sixteenth the cost and about one-thirtieth the time and
effort. If the experimental design requires only quantification of
alleles with frequencies greater than 0.01 (i.e., prevalence more
than 1%), then there appears to be no disadvantage to using a larger, about 250-individual DNA pooling strategy at an additional
doubling of the cost savings. These cost and time efficiencies are
expected to further improve with double-end reading and further

technological advances, and the protocols can be applied to any
genes in virtually any population of interest. For example, pooled
resequencing of large, existing cardiovascular study populations
could rapidly identify and quantify biologically relevant SNPs in
cardiac contractile protein genes, ion pump and channel genes, or
transcription factor genes (30–32).
SNP associations with systolic heart failure. The current study focused
on 4 signaling genes, selected for their potential importance in
cardiac disease and (in these initial pooled resequencing studies)
for their uncomplicated genetic structure. Polymorphisms of the
α1-adrenergic receptor, encoded by ADRA1A, have been linked with
hypertensive disease in some, but not all, populations (33–35). It

Table 4
Comparative allele frequencies of common HSPB7 SNPs in Caucasian heart failure
dbSNP

Position

Type

rs3738640
rs945416
rs732286
rs3883891
rs1763596
rs1739845
rs3738643
rs1739844
rs1763597
rs1739843
rs12758813
rs1739842
rs1763598
rs1739841
rs1763599
rs61783988
rs761760
rs761759
rs1739840

–8
+57
+99
I1+177
I1-133
I1-113
I2+245
I2+247
I2+272
I2+315
I2+490
I2-594
I2-483
I2-473
I2-348
I2-343
I2-165
I2-96
+351

5′UTR
Coding S
Coding S
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Intronic
Coding S

Major Minor
allele allele
G
C
T
A
G
G
C
A
G
A
C
A
A
T
G
T
T
T
C

Codon

A		
T
S19S
C
A33A
G		
A		
T		
G		
G		
A		
G		
T		
C		
G		
C		
A		
C		
C		
A		
T
T117T

Primary Primary
controls cases
0.106
0.538
0.517
0.373
0.538
0.050
0.112
0.511
0.528
0.543
0.417
0.524
0.878
0.480
0.601
0.078
0.531
0.552
0.473

0.102
0.606
0.594
0.424
0.619
0.052
0.098
0.589
0.618
0.624
0.450
0.615
0.898
0.578
0.666
0.075
0.598
0.632
0.399

Fisher
exact

Adjusted
c2

0.6847
0.0001A
<0.0001A
0.0032
<0.0001A
0.8732
0.2454
<0.0001A
<0.0001A
<0.0001A
0.0696
<0.0001A
0.0796
<0.0001A
0.0001A
0.7903
0.0001A
<0.0001A
<0.0001A

0.7246
0.0001A
<0.0001A
0.0040
<0.0001A
0.8168
0.2156
<0.0001A
<0.0001A
<0.0001A
0.0654
<0.0001A
0.0836
<0.0001A
0.0002A
0.7652
0.0002A
<0.0001A
<0.0001A

Secondary Secondary Fisher
controls
cases
exact

Adjusted
c2

0.510
0.489

0.582
0.575

0.0025B 0.0001B
0.0003B <0.0001B

0.506

0.576

0.003B

0.480
0.515
0.495

0.571
0.575
0.585

0.0001B <0.0001B
0.0109B 0.0008B
0.0001B <0.0001B

0.480

0.568

0.0002B <0.0001B

0.405
0.554

0.506
0.633

<0.0001B <0.0001B
0.0006B <0.0001B

0.484
0.456
0.561

0.570
0.581
0.443

0.0003B <0.0001B
<0.0001B <0.0001B
<0.0001B <0.0001B

0.0001B

Allele frequencies of common SNPs in HSPB7 from Illumina resequencing of 7 DNA pools from 625 nonaffected primary controls, 12 DNA pools from
1,117 primary cases, 4 DNA pools from 311 nonaffected secondary controls, and 10 DNA pools from 825 secondary cases. For SNPs in HapMap, the rs
number from dbSNP (19) is shown. Position is from the translation initiation codon. I1, first intron; I2, second intron; S, synonymous; UTR, untranslated
region. Values in the codon column show the amino acid. Comparative allele frequencies of all 37 common target gene SNPs are given in Supplemental
Table 2. Statistical comparisons used Fisher exact and adjusted χ2 tests as described in Methods. AP < 0.0014, the threshold for the primary study
(α = 0.05, 2-tailed test; n = 37). BP < 0.0212, the threshold for the replication study (α = 0.05, 2-tailed test; effective number of independent SNPs, 2.36).
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is striking that our studies detected 14 nonsynonymous polymorphisms of this receptor, 8 of which were rare and not previously
reported in dbSNP (Table 2 and ref. 19). To our knowledge, there
are no published reports of associations between ADRA1A variants and development of heart failure, and no significant associations were detected in our studies. Likewise, β2-adrenergic receptors, encoded by ADRB2, mediate the cardiac inotropic response to
catecholmines and are the targets of β-blocking drugs. This gene
is highly polymorphic (10 nonsynonymous SNPs in our study,
5 rare and previously unreported), but does not appear to contribute to heart failure risk in our present study or in previous studies (36). Phospholamban, encoded by PLN, is a critical regulator
of cardiomyocyte calcium cycling that transmits inputs from the
β-adrenergic receptor system to the major sarcoplasmic reticulum
calcium reuptake pump, SERCA2 (37). In dramatic contrast to
the results for the 2 adrenergic receptors, not a single nonsynonymous polymorphism for PLN was detected in the more than 2,600
individuals of our cohort. This remarkable degree of amino acid
sequence conservation was consistent with the severe pathological consequences previously described with loss-of-function PLN
mutants. Substitution of cysteine for arginine at amino acid 9 (16),
introduction of a premature stop codon at amino acid 39 (38), and
deletion of arginine 14 (17, 39) each cause a familial cardiomyopathy with potentially lethal repercussions.
HSPB7, also referred to as cvHSP (18), has not previously been
systematically examined for genetic variation. However, because
an array-based analysis of approximately 2,000 candidate cardiovascular genes found a significant association between the
intronic HSPB7 SNP rs1739843 and heart failure (T.P. Cappola
and G.W. Dorn II, unpublished observations), we included it in
our resequencing study. We detected 39 HSPB7 SNPs, of which 18
were either rare or observed exclusively in the African American
subgroup (Table 2); to our knowledge, all were previously unreported. Of the HSPB7 SNPs, 12 were associated with systolic heart
failure, and these associations were independently validated in a
second heart failure population. HSPs are upregulated in response
to stress and exhibit a variety of cytoprotective effects through
their function as molecular chaperones (40). A nonsynonymous
polymorphism of HSP20 that lacks its characteristic cytoprotective effects has been described previously (41). However, none of
the associated HSPB7 SNPs changed an amino acid in HSPB7.
To determine whether a functionally significant noncoding SNP
might account for the association with heart failure, we examined
the most recent list from the miRBase database of all the genomic
locations of known human miR precursors; none were within
10 Mb of HSPB7 (our unpublished observations). We also subjected the area we sequenced to TargetScan analysis, which showed
only 1 SNP (that occurred only in African Americans and was not
significantly associated in the case-control analysis) in a poorly
conserved binding site for hsa-miR-1207-5p (our unpublished
observations). Finally, we looked at proximity of the HSPB7 SNPs
to splice acceptor and splice donor sites; none were closer than 50
nucleotides (our unpublished observations). However, because the
associated HSPB7 SNPs were in linkage disequilibrium within a
haplotype block that extends beyond the HSPB7 gene, we speculate
that the causative genetic event may be in another gene or in the
intergenic region. Further examination of this locus by resequencing may help establish a mechanism for the genetic findings.
Nonsynonymous signaling gene SNPs. A major advantage of exomic
sequencing is the potential to identify rare gene variants typically

missed by linkage analysis with microsatellite markers or marker
SNPs. Any specific rare SNP, by definition, affects a small proportion of individuals and therefore tends to be discounted. As a class,
however, rare SNPs can be collectively common, as evidenced by
our observation that, of the 129 SNPs identified in this study, 74
(57.4%) had a prevalence of less than 1%. Because pathological
effects of variant gene products produce selective pressure against
sequence variation, a high proportion of rare nonsynonymous
SNPs can be detrimental (27) and are therefore particularly important to catalog. Here, we identified 23 novel nonsynonymous SNPs
(Supplemental Table 6) that — although they were not associated
with increased risk for development of systolic heart failure in this
study — may merit closer examination as potential modifiers of
sporadic cardiomyopathy or of other diseases. To that end, using
bioinformatics to classify nonsynonymous SNPs by their probability for pathological impact provides a mechanism for initial
titration of SNPs for further mechanistic evaluation.
Limitations. Pooled sequencing, as used herein, can rapidly generate accurate SNP frequency data for a large study cohort, but
does not provide genetic information at the individual level. Consequently, the data are not readily useful for assessment of relative
risk. However, an estimate of carrier prevalence can be generated if
one assumes that the SNPs conform to the predictions of HardyWeinberg equilibrium (42). With this caveat, the HSPB7 SNPs identified herein increase the odds of developing systolic heart failure
by an average of 1.55 ± 0.02–fold (Supplemental Table 7).
Pooled exomic sequencing is optimized for large-scale comparisons of allele frequencies between, or within, populations, as with
case-control studies of disease or studies comparing populations
of genetic/geographic ancestry. We have found that the technique
and data analysis pipeline can be modified to incorporate individual PCR amplification and DNA barcoding prior to DNA pooling to obtain personal sequence, while taking advantage of the
high throughput and efficiencies of pooled resequencing on the
Illumina Genome Analyzer II (G.W. Dorn II and S.J. Matkovich,
unpublished observations).
The nature of population genetics research, either using high-density genome-wide SNP microarrays to identify loci linked with disease or using targeted subgenome resequencing to identify specific
SNPs associated with disease, is that the significant genetic events
do not necessarily define the causal genetic events. Our study provides an example of this, in that multiple replicated and validated
HSPB7 SNPs associated with development of systolic heart failure
in Caucasians do not, as far as we can determine using available
bioinformatics resources, affect gene or protein function. Thus, the
mechanism for these findings is unclear and will require both additional resequencing and case-control studies to identify linked SNPs
that may be causal and wet laboratory work to define the functional
impact of those SNPs at the cellular and organism levels.
Our SNP discovery efforts were performed in Caucasians and
African Americans, and the heart failure case-control study was
limited to systolic heart failure in Caucasians. The impact of our
findings was not addressed in groups with different geographic
ancestry, such as Hispanic and Asian populations, although the
approach described herein would be ideal to do so.
In summary, we have demonstrated the accuracy and utility
of pooled sequencing to identify previously unknown rare gene
variants, to compare polymorphism expression between different
ancestral populations, and to identify novel associations between
HSPB7 polymorphisms and sporadic systolic heart failure in Cau-
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casians. This approach will be generally useful to identify diseaseassociated SNPS in gene-ontology clusters informed by arraybased genome-wide association studies and by existing databases
of gene expression or as suggested by biological rationale.
Methods
Study subjects. Human study protocols were approved by the Institutional
Review Boards of the University of Cincinnati or the University of Pennsylvania. All subjects provided written informed consent. Subjects with
systolic heart failure were recruited, from patients presenting to the heart
failure referral program at the University of Cincinnati or the University
of Pennsylvania, into 1 of 2 longitudinal studies of heart failure genomics funded by the National Heart, Lung, and Blood Institute (NHLBI; P50
HL77101 and R01 HL88577). Enrollment criteria were age 18–80 years,
clinical diagnosis of systolic heart failure, and documented abnormal left
ventricular function (ejection fraction <40%) by noninvasive cardiac imaging. African American inclusion at greater than 25% of the total cohort was
part of the NHLBI-approved study design. Nonaffected controls, in whom
clinical heart failure was not present, echocardiographic left ventricular
function was normal (ejection fraction >50%, no wall motion abnormalities), and there was no evidence for clinically significant coronary artery
disease, were from the greater Cincinnati and Philadelphia metropolitan
areas. DNA from a total of 2,606 individuals was studied in the primary
cohort: 1,117 Caucasian heart failure subjects, 625 Caucasian nonaffected
controls, 628 African American heart failure subjects, and 236 African
American nonaffected controls. The secondary replication cohort consisted of 859 Caucasian systolic heart failure cases and 311 Caucasian
nonaffected controls. Detailed clinical features of these heart failure study
populations were recently reported (20).
DNA preparation, pooling, and amplification. Genomic DNA was isolated and
extracted using the Gentra Puregene genomic DNA purification kit (Qiagen)
and individually quantified by PicoGreen (Invitrogen) fluorescence in a 96well format. For our initial validation experiments, 25 ng DNA from each
individual was combined into pools, as shown in Supplemental Figure 1.
DNA segments containing the regions of interest were individually PCR
amplified using specific primers (Supplemental Table 8) and PfuUltra highfidelity polymerase (Stratagene) from each of the pools, using an average of
30 diploid genomes (approximately 0.2 ng DNA) per individual as input into
a total of 7 PCR reactions that included 9,389 bases from 4 genes: ADRA1A,
ADRB2, HSPB7, and PLN (Supplemental Table 8). Preparation of the PCR
products for sequencing on the Illumina Genome Analyzer I or II was as
described previously (11). Briefly, amplicons were purified from primers and
residual nucleotides by Qiaquick column separation (Qiagen), combined
into mixtures containing an equivalent number (1 × 1011) of molecules of
each amplicon, and concatenated overnight at 22°C with T4 DNA ligase and
T4 polynucleotide kinase (New England Biolabs) in the presence of 15% (w/v)
polyethylene glycol, MW8000 (Sigma-Aldrich). pBluescript control DNA
amplicons were included in ligations to monitor base calling accuracy. After
10-fold dilution in buffer PB (Qiagen), random fragmentation by sonication (Diagenode Bioruptor XL), and purification on Qiaquick columns (Qiagen), the DNA was end repaired, ligated to Illumina sequencing adapters,
and prepared for analysis per Illumina protocol. Individual resequencing of
ADRA1A exon 2 in the entire primary cohort was performed by dye terminator sequencing using an ABI 3730xl capillary sequencer (17, 43).
Sequence analysis. As previously demonstrated, the likelihood of sequencing errors across the 36-bp Illumina read across bases 1–12 averages
0.00065, rises dramatically after base 12, and can vary significantly from
run to run (11). To model these errors, a 1,655-bp amplicon from the pBluescript backbone was incorporated into the ligation of PCR products and
used to define an error model for each sequencing run. Sequencing output
288

was aligned against an annotated reference gene sequence, consisting of
only the regions amplified, downloaded from the UCSC Genome Browser
(44). Illumina reads were aligned against the reference by allowing 2 mismatches or fewer for each read. Any read with more than 2 mismatches or
that aligned to multiple locations in the reference sequence was eliminated
from SNP calling. SNPSeeker used only the first 12 highly accurate bases
of each read along with a second-order dependency model to identify SNPs
in all regions of interest. Therefore, whereas all 36 bases of each read were
used for alignment to reference, only bases 3–12 of each 36-base read were
effectively used for SNP identification. Because a single allele occurs at a
frequency of 0.002 in a pool of 250 individuals (and at a frequency of 0.005
in a pool of 100 individuals), a singleton will be present at a frequency at
least about 3-fold more prevalent than error in a given sequencing lane. We
defined common SNPs as those occurring at a frequency of at least 0.01 in
subjects of similar geographic ancestry, whereas the lower limit of detection for rare SNPs was a frequency of 0.0003 for all Caucasians (1 allele in
the entire cohort of 1,742 individuals) and a frequency of 0.0006 for all
African Americans (1 allele in 864 individuals).
For each gene, all available sequences were downloaded from dbSNP (19)
and mapped onto an annotated reference gene sequence downloaded from
the UCSC Genome Browser (44). Names were assigned according to the
nomenclature suggested by the Human Genome Variation Society (45), in
which the +1 position denotes the translation initiation codon, and numbering of SNPs within introns depends on proximity to the nearest exon.
Comparative genomic analysis. SIFT (28) and PolyPhen (29) analyses were
conducted with the default parameter settings.
Statistics. Allele frequencies for all SNPs were compared with a Pearson’s
correlation coefficient. To assess differences in clinical variables, 2-tailed
Student’s t test was used. Fisher exact test or adjusted χ2 test (see below)
were used to compare allele frequencies. The P level threshold for significance in the primary heart failure case-control analysis was P < 0.0014,
using a Bonferroni correction for multiple testing (n = 37 common SNPs
at α = 0.05). Prior to the replication study, linkage between the associated
HSPB7 SNPs was assessed. Allele frequency correlations across pools and
eigenvalues were calculated using the R package per Gao et al. (46), and
these were used to derive the effective number of independent SNPs (Meff)
by the equation Meff = 1 + [(M – 1) (1 – [Var(λobs)]/M)], in which M is the
total number of variables in the matrix and Var(lobs) is the variance of the
observed eigenvalues (47). The calculated Meff of 2.37 was then used in a
Bonferroni correction to derive a threshold P value of P < 0.0212 (α = 0.05).
To account for variance due to DNA pooling, an estimate of pooling error
was calculated according to Visscher and Le Hellard (48). The resulting
error factor of 0.014 was then used to adjust the χ2 test statistic.
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